Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:21:01.857Z.
Calculation as of: 2026-10-06T18:21:01.857Z.
Quote observation: 2026-10-06T18:18:53.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc6ba70d6a7a815a92143918ed9b9c2f02635c4477fd12c4733392629ce909df
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$82.19M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$80.90M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.58M
EV/EBITDA Ratio
N/A
TTM Avg
12.88x
3Y Avg
47.67x
5Y Avg
47.67x
Market Cap
$84.22M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | $82.85M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.64M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $82.50M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.78M | N/A | N/A | N/A | N/A |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.19M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.90M | N/A | N/A | N/A | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $83.58M | N/A | 12.88x | 47.67x | 47.67x |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.22M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.14M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $83.61M | N/A | 8.06x | 8.06x | 8.06x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
